CAS NO: | 2820336-67-0 |
包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
生物活性 | JBJ-09-063 is a mutant-selective allostericEGFRinhibitor withIC50s of 0.147 nM, 0.063 nM, 0.083 nM and 0.396 nM forEGFRL858R,EGFRL858R/T790M,EGFRL858R/T790M/C797S and EGFRLT/L747S. JBJ-09-063 effectively reducesEGFR,Aktand ERK1/2 phosphorylation. JBJ-09-063 is effective acrossEGFRtyrosine kinase inhibitor (TKI)-sensitive and resistant models. JBJ-09-063 can be used for researching EGFR-mutant lungcancer[1]. | ||||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||||
体外研究 (In Vitro) | JBJ-09-063 is remarkably effective at inhibiting cell growth and leads to a significant increase in apoptosis, even though H3255GR cells are resistant to gefitinib as a single agent, as they contain an EGFR T790M mutation[1]. | ||||||||||||||||||
体内研究 (In Vivo) | JBJ-09-063 (3 mg/kg i.v., 20 mg/kg p.o.) exhibits favorable pharmacokinetics properties and is sufficiently stable to deliver good efficacy upon oral dosing[2].
| ||||||||||||||||||
分子量 | 556.65 | ||||||||||||||||||
Formula | C31H29FN4O3S | ||||||||||||||||||
CAS 号 | 2820336-67-0 | ||||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||||
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. | ||||||||||||||||||
溶解性数据 | In Vitro: DMSO : 120 mg/mL(215.58 mM;Need ultrasonic) 配制储备液
|